Bill Maher

Are peptides the be all end all?

Well, no, not necessarily.

Lifestyle factors and drugs in some cases are lifestyle factors and other things.

But the key here is that if a drug stands to make a company a lot of money, then there's an incentive to regulate this stuff.

So we're in this weird landscape where I really think you have two populations of slightly overlapping populations of people.

You have people that

Their level of astringency is if it's not FDA approved from a traditional company, from pharma, multiple randomized controlled trials, I don't want to take it.

I'm not putting it anywhere near my family or anyone I know.

And then you have a separate category of people, which is quite large, who say the fact that something is from pharma, the fact that it's associated with the FDA is the major reason why they do want to take something.

And this is where I think I'm so tired of looking at traditional media coverage of like peptides is where they throw it out like a dog's breakfast of all these different things lump and just say, peptides don't do anything.

Really?

Insulin doesn't do anything for a diabetic?

Really?

The GLPs don't do anything?

The root of all of this is control of the patent and financial pipeline, which is not to say that I can't relate.

I mean, Lilly, I have no stock in Lilly.

I kind of wish I did.

I mean, it's over a thousand bucks right now.

It was a couple hundred bucks a few years ago.

Lilly invested hundreds of millions of dollars.